Market Overview:
The global oncology clinical trial market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of cancer, rising demand for novel therapies and increasing number of clinical trials. Based on type, the prostate cancer segment is expected to account for the largest share of the global oncology clinical trial market in 2018. This segment is also projected to grow at a CAGR of 7.8% from 2018 to 2030.
Product Definition:
An oncology clinical trial is a study of new treatments for cancer. Clinical trials are important because they allow doctors to test new treatments and learn how well they work.
Prostate Cancer:
Prostate cancer is the cancer that occurs in the prostate gland, which is responsible for producing semen. The majority of prostate cancers are diagnosed in men aged 65 years and above. Prostate cancer has a slow growth rate; hence it is termed as a tumor of slow growth or low-risk type.
Lung Cancer:
Lung cancer is a type of cancer that begins in the lung tissues and bronchus. The most common types of lung cancers are non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). NSCLCs accounts for majority of the cases globally, while SCLCs are more prevalent in U.S., followed by Japan.
Application Insights:
The hospital application segment dominated the global oncology clinical trial market in 2017. This can be attributed to the increasing prevalence of cancer and rising awareness about available treatment options. According to data published by WHO, around 1 in 6 women and 1 in 5 men are estimated to develop cancer during their lifetime. In addition, as per estimates from the American Cancer Society, around 210,170 new cases of invasive prostate cancer were reported globally in 2018 along with more than 40K new cases of non-invasive prostate cancer. Thus, a large patient base is expected to drive demand for oncology drugs across various applications over the forecast period.
Clinic application segment is anticipated to witness lucrative growth over the forecast period owing to an increase in number of clinics offering Oncology Drug Therapy (ODT).
Regional Analysis:
North America dominated the global oncology clinical trial market in 2017. This can be attributed to the presence of major players, increased funding for cancer research, and rising incidence of various types of cancers in this region. For instance, as per the American Cancer Society estimates around 1,762,780 new cases were estimated to be diagnosed in North America during 2016 and is expected to rise till 2035 resulting in an urgent need for effective treatment options.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing R&D investments by pharmaceutical companies coupled with growing awareness about available treatments among patients & physicians. In addition it attracts many foreign investors who are keen on investing in emerging markets offering huge potential opportunities for growth through acquisition or establishment of a new facility within Asia Pacific region thus contributing significantly towards overall revenue generation within this segment (preliminary estimates).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for oncology clinical trial market. According to World Health Organization (WHO), the number of new cases of cancer is expected to rise from 14 million in 2012 to 22 million by 2030. This will create a huge demand for oncology drugs and therapies, which will subsequently drive the growth of oncology clinical trial market.
- Rising prevalence of lifestyle diseases: The rising prevalence of lifestyle diseases such as obesity, diabetes, and hypertension is also contributing to the growth of oncology clinical trial market. These diseases are known risk factors for various types cancers such as breast cancer, colorectal cancer, and prostate cancer. As a result, there is an increasing demand for effective diagnosis and treatment options for these cancers, which is driving the growth of oncology clinical trial market.
- Technological advancements in diagnostics & therapeutics: The technological advancements in diagnostics & therapeutics are another major factor fuelling the growth Oncology Clinical Trial Market . For instance , development o f targeted therapies that specifically attack tumor cells without affecting normal cells has revolutionized treatment options available fo r patients with certain types o f cancers . Similarly , advancement s i n diagnostic technologies such as positron emission tomography (PET) scanning have helped physicians detect tumors at early stages when they are more treatable . All these technological advancements are helping researchers develop better drugs and therapies thus propelling
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncology Clinical Trial Market Research Report
By Type
Prostate Cancer, Lung Cancer, Breast Cancer, Leukemia, Others
By Application
Hospital, Clinic, Lab
By Companies
IQVIA, Charles River Laboratory, ICON Plc, Medelis, Inc., Medpace Holdings, Inc., PAREXEL International, Pharmaceutical Product Development, LLC, Pivotal, PRA Health Sciences, Syneos Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Oncology Clinical Trial Market Report Segments:
The global Oncology Clinical Trial market is segmented on the basis of:
Types
Prostate Cancer, Lung Cancer, Breast Cancer, Leukemia, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Lab
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- IQVIA
- Charles River Laboratory
- ICON Plc
- Medelis, Inc.
- Medpace Holdings, Inc.
- PAREXEL International
- Pharmaceutical Product Development, LLC
- Pivotal
- PRA Health Sciences
- Syneos Health
Highlights of The Oncology Clinical Trial Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Leukemia
- Others
- By Application:
- Hospital
- Clinic
- Lab
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncology Clinical Trial Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A clinical trial is a research study in which patients with a disease or condition are given an experimental treatment. Clinical trials are often used to find new ways to treat diseases, and can also help scientists learn more about the causes of diseases.
Some of the major players in the oncology clinical trial market are IQVIA, Charles River Laboratory, ICON Plc, Medelis, Inc., Medpace Holdings, Inc., PAREXEL International, Pharmaceutical Product Development, LLC, Pivotal, PRA Health Sciences, Syneos Health.
The oncology clinical trial market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oncology Clinical Trial Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Oncology Clinical Trial Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Oncology Clinical Trial Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Oncology Clinical Trial Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Oncology Clinical Trial Market Size & Forecast, 2018-2028 4.5.1 Oncology Clinical Trial Market Size and Y-o-Y Growth 4.5.2 Oncology Clinical Trial Market Absolute $ Opportunity
Chapter 5 Global Oncology Clinical Trial Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oncology Clinical Trial Market Size Forecast by Type
5.2.1 Prostate Cancer
5.2.2 Lung Cancer
5.2.3 Breast Cancer
5.2.4 Leukemia
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oncology Clinical Trial Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oncology Clinical Trial Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Lab
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oncology Clinical Trial Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oncology Clinical Trial Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oncology Clinical Trial Analysis and Forecast
9.1 Introduction
9.2 North America Oncology Clinical Trial Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oncology Clinical Trial Market Size Forecast by Type
9.6.1 Prostate Cancer
9.6.2 Lung Cancer
9.6.3 Breast Cancer
9.6.4 Leukemia
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oncology Clinical Trial Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Lab
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oncology Clinical Trial Analysis and Forecast
10.1 Introduction
10.2 Europe Oncology Clinical Trial Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oncology Clinical Trial Market Size Forecast by Type
10.6.1 Prostate Cancer
10.6.2 Lung Cancer
10.6.3 Breast Cancer
10.6.4 Leukemia
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oncology Clinical Trial Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Lab
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oncology Clinical Trial Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oncology Clinical Trial Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oncology Clinical Trial Market Size Forecast by Type
11.6.1 Prostate Cancer
11.6.2 Lung Cancer
11.6.3 Breast Cancer
11.6.4 Leukemia
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oncology Clinical Trial Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Lab
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oncology Clinical Trial Analysis and Forecast
12.1 Introduction
12.2 Latin America Oncology Clinical Trial Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oncology Clinical Trial Market Size Forecast by Type
12.6.1 Prostate Cancer
12.6.2 Lung Cancer
12.6.3 Breast Cancer
12.6.4 Leukemia
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oncology Clinical Trial Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Lab
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oncology Clinical Trial Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oncology Clinical Trial Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oncology Clinical Trial Market Size Forecast by Type
13.6.1 Prostate Cancer
13.6.2 Lung Cancer
13.6.3 Breast Cancer
13.6.4 Leukemia
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oncology Clinical Trial Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Lab
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oncology Clinical Trial Market: Competitive Dashboard
14.2 Global Oncology Clinical Trial Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 IQVIA
14.3.2 Charles River Laboratory
14.3.3 ICON Plc
14.3.4 Medelis, Inc.
14.3.5 Medpace Holdings, Inc.
14.3.6 PAREXEL International
14.3.7 Pharmaceutical Product Development, LLC
14.3.8 Pivotal
14.3.9 PRA Health Sciences
14.3.10 Syneos Health